Fibrinogen and factor XIII A-subunit genotypes interactively influence C-reactive protein levels during inflammation

Annals of the Rheumatic Diseases

Volumn 71, Issue 7, 2012, Pages 1163-1169

  Hoppe, Berthold ^a   Häupl, Thomas ^a   Skapenko, Alla ^b   Ziemer, Sabine ^a   Tauber, Rudolf ^a   Salama, Abdulgabar ^a   Schulze Koops, Hendrik ^b   Burmester, Gerd Rüdiger ^a   Dörner, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FIBRINOGEN; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8A; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; FIBRINOGEN B BETA CHAIN; HLA DRB1 ANTIGEN; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ADULT; ALLELE; ANTIBODY DETECTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; RHEUMATOID ARTHRITIS;

ACUTE-PHASE REACTION; ADULT; C-REACTIVE PROTEIN; FACTOR XIIIA; FEMALE; FIBRINOGEN; GENOTYPE; HUMANS; MALE; MIDDLE AGED;

EID: 84862578144     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200738     Document Type: Article

References (49)

1. Loof TG, Mörgelin M, Johansson L, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011;118:2589-98.
2. Senior RM, Skogen WF, Griffin GL, et al. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest 1986;77:1014-19. (Pubitemid 16067979)
3. Skogen WF, Senior RM, Griffin GL, et al. Fibrinogen-derived peptide B beta 1-42 is a multidomained neutrophil chemoattractant. Blood 1988;71:1475-9.
4. Liu X, Piela-Smith TH. Fibrin(ogen)-induced expression of ICAM-1 and chemokines in human synovial fibroblasts. J Immunol 2000;165:5255-61.
5. Belkin AM, Tsurupa G, Zemskov E, et al. Transglutaminase-mediated oligomerization of the fibrin(ogen) alphaC domains promotes integrin-dependent cell adhesion and signaling. Blood 2005;105:3561-8. (Pubitemid 40628201)
6. Lanir N, Ciano PS, Van de Water L, et al. Macrophage migration in fibrin gel matrices. II. Effects of clotting factor XIII, fibronectin, and glycosaminoglycan content on cell migration. J Immunol 1988;140:2340-9. (Pubitemid 18098496)
7. Flick MJ, Du X, Witte DP, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 2004;113:1596-606. (Pubitemid 39071683)
8. Sun H, Ringdahl U, Homeister JW, et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 2004;305:1283-6. (Pubitemid 39129231)
9. Sun H, Wang X, Degen JL, et al. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2009;113:1358-64.
10. Persson K, Russell W, Mörgelin M, et al. The conversion of fibrinogen to fibrin at the surface of curliated Escherichia coli bacteria leads to the generation of proinflammatory fibrinopeptides. J Biol Chem 2003;278:31884-90. (Pubitemid 37048373)
11. Forsyth CB, Solovjov DA, Ugarova TP, et al. Integrin alpha(M)beta(2)- mediated cell migration to fibrinogen and its recognition peptides. J Exp Med 2001;193:1123-33. (Pubitemid 32488365)
12. Petzelbauer P, Zacharowski PA, Miyazaki Y, et al. The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med 2005;11:298-304. (Pubitemid 40460558)
13. Ho PP, Lee LY, Zhao X, et al. Autoimmunity against fibrinogen mediates inflammatory arthritis in mice. J Immunol 2010;184:379-90.
14. Flick MJ, LaJeunesse CM, Talmage KE, et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest 2007;117:3224-35. (Pubitemid 350096980)
15. Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-73.
16. Masson-Bessière C, Sebbag M, Girbal-Neuhauser E, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001;166:4177-84.
17. Ariëns RA, Lai TS, Weisel JW, et al. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002;100:743-54.
18. Lim BC, Ariëns RA, Carter AM, et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003;361:1424-31.
19. Ariëns RA, Philippou H, Nagaswami C, et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000;96:988-95.
20. Jacquemin B, Antoniades C, Nyberg F, et al. Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol 2008;52:941-52.
21. Reiner AP, Carty CL, Carlson CS, et al. Association between patterns of nucleotide variation across the three fibrinogen genes and plasma fibrinogen levels: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Thromb Haemost 2006;4:1279-87.
22. Siegerink B, Rosendaal FR, Algra A. Genetic variation in fibrinogen; its relationship to fibrinogen levels and the risk of myocardial infarction and ischemic stroke. J Thromb Haemost 2009;7:385-90.
23. Evans DM, Marchini J, Morris AP, et al. Two-stage two-locus models in genomewide association. PLoS Genet 2006;2:e157.
24. Kolz M, Koenig W, Müller M, et al.; AIRGENE Study Group. DNA variants, plasma levels and variability of C-reactive protein in myocardial infarction survivors: results from the AIRGENE study. Eur Heart J 2008;29:1250-8. (Pubitemid 351768118)
25. Karakas M, Baumert J, Greven S, et al. Reproducibility in serial C-reactive protein and interleukin-6 measurements in post-myocardial infarction patients: results from the AIRGENE study. Clin Chem 2010;56:861-4.
26. Hoppe B, Häupl T, Egerer K, et al. Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis. Ann Rheum Dis 2009;68:898-903.
27. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
28. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
29. von Versen-Hoeynck FM, Hubel CA, Gallaher MJ, et al. Plasma levels of inflammatory markers neopterin, sialic acid, and C-reactive protein in pregnancy and preeclampsia. Am J Hypertens 2009;22:687-92.
30. Ernst GD, de Jonge LL, Hofman A, et al. C-reactive protein levels in early pregnancy, fetal growth patterns, and the risk for neonatal complications: the Generation R Study. Am J Obstet Gynecol 2011;205:132.e1-132.e12.
31. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 2010;30:1672-8.
32. Hoppe B, Heymann GA, Koscielny J, et al. Screening for multiple hereditary hypercoagulability factors using the amplification refractory mutation system. Thromb Res 2003;111:115-20. (Pubitemid 37485935)
33. Hoppe B, Tolou F, Dörner T, et al. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population. Thromb Haemost 2006;96:465-70. (Pubitemid 44560680)
34. Hoppe B, Heymann GA, Kiesewetter H, et al. Identification and characterization of a novel HLA-DRB1 allele, DRB1&z.ast;0830&z.ast;. Tissue Antigens 2005;66:160-2. (Pubitemid 41025943)
35. Schlesselman JJ. Case-Control Studies: Design, Conduct, Analysis. New York, Oxford: Oxford University Press, 1982.
36. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics 2000;56:645-6. (Pubitemid 30422662)
37. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5. (Pubitemid 40202029)
38. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
39. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost 2009;102:360-70.
40. Sánchez-Pernaute O, Largo R, Calvo E, et al. A fibrin based model for rheumatoid synovitis. Ann Rheum Dis 2003;62:1135-8.
41. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001;167:2887-94. (Pubitemid 32768923)
42. Rhodes B, Merriman ME, Harrison A, et al. A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation. PLoS Med 2010;7:e1000341.
43. Benjamin EJ, Dupuis J, Larson MG, et al. Genome-wide association with select biomarker traits in the Framingham Heart Study. BMC Med Genet 2007;8 (Suppl 1):S11.
44. Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009;302:37-48.
45. Ridker PM, Pare G, Parker A, et al. Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet 2008;82:1185-92.
46. Kovar FM, Marsik C, Jilma B, et al. The fibrinogen -148 C/T polymorphism influences inflammatory response in experimental endotoxemia in vivo. Thromb Res 2007;120:727-31. (Pubitemid 47268043)
47. van der Helm-van Mil AH, Detert J, le Cessie S, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008;58:2241-7.
48. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
49. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45:1558-65. (Pubitemid 44817065)